Safety and Antimicrobial Resistance of Mass Administration of Azithromycin in Children 1-59 months in Nigeria (SARMAAN II) is the second phase of child survival implementation research ongoing in seven (7) states of the country and conducted by the Nigerian Institute of Medical Research, Lagos.
In order to effectively fulfil the objectives of the expansion, we seek dedicated, self-motivated, team players to join our dynamic team:
